AAPL

TSLA

AMZN

META

AMD

NVDA

PEP

COST

ADBE

GOOG

AMGN

HON

INTC

INTU

NFLX

ADP

SBUX

MRNA

Markets

PFE

Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics

May 07, 2026 — 05:00 am EDT

Written by

Keith Speights for

The Motley Fool->

Key Points

- Pfizer's cash flow visibility is now greater thanks to legal wins.

- The company isn't planning a mega-merger that could affect its ability to cover the dividend.

- Pfizer now has "greater confidence" that it will deliver solid growth for years to come.

- 10 stocks we like better than Pfizer ›

The higher the dividend yield, the more investors tend to worry. Pfizer (NYSE: PFE) boasts a forward dividend yield of 6.5%, the highest yield among large-cap healthcare stocks. Unsurprisingly, some have viewed Pfizer as a yield trap.

While Pfizer's dividend yield may have looked too good to be true for some investors, that shouldn't be the case now. The company provided its first-quarter update on Tuesday, May 5, 2026. And I think that management just silenced the skeptics.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Image source: Getty Images.

Pfizer's reassuring news for income investors

Pfizer CEO Albert Bourla addressed any doubts about the drugmaker's commitment to its dividend in the Q1 call, stating, "We intend to maintain and over time, grow our dividend as we continue to delever and build long-term value." CFO David Denton reinforced this message, saying that Pfizer's strategy includes "maintaining and over time growing our dividend."

Were those just meaningless words? I don't think so. One reason is that Pfizer now has greater cash flow visibility thanks to legal settlements related to the Vyndamax patent infringement and a Belgian court ruling on Comirnaty contracts with European Union countries. These two developments significantly improve Pfizer's ability to support its dividend.

Pfizer has made large acquisitions in the past that resulted in dividend cuts. Could history repeat itself? Bourla was asked about this possibility in the Q1earnings call He replied that Pfizer will always explore merger and acquisition opportunities, but the company isn't planning to pursue a large-scale merger. Bourla added that the disruption of a mega merger would negatively affect the organization's execution of its artificial intelligence (AI) transformation.

The near term looks good for Pfizer. The company generated more operating cash flow in Q1 than it needed to cover the dividend. Pfizer beat Wall Street's expectations with its Q1 results. Denton hinted that the drugmaker would probably have raised its guidance were it not for his "philosophy of not really adjusting in Q1."

The longer term looks bright, too. Management now has "greater confidence" that the company will deliver high single-digit revenue growth beginning in 2029. Pfizer's pipeline programs have promising prospects, especially its cancer and obesity therapies in development.

A yield trap? No way.

Had Pfizer's Q1 update given investors reasons to worry about weak cash flow, legal questions, and uncertainty related to growth, the skeptics viewing the stock as a yield trap would have had some ammunition. However, that wasn't the case at all. Instead, we heard Pfizer discuss strong cash flow generation, key legal victories, and increased confidence in solid growth in the years ahead.

Pfizer's dividend appears to be safer than some thought before the Q1 results. The 6.5% yield isn't too good to be true. Here's what is true: Pfizer is one of the most attractive dividend stocks on the market right now.

Should you buy stock in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $473,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,204,650!*

Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of May 7, 2026.